Environmental Carcinogenesis Unit, Ospedale Policlinico San Martino, Genoa, Italy.
Unit of Clinical Epidemiology, IRCCS Ospedale Policlinico San Martino, 16131 Genoa, Italy.
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108358. doi: 10.1016/j.mrrev.2020.108358. Epub 2020 Nov 28.
A systematic review and a meta-analysis were performed on 19 studies on head and neck cancer (HNC) and 21 studies on breast cancer (BC) to evaluate the application of micronucleus (MN) assay as a predictive and prognostic test for cancer risk. In these studies the MN test was applied in peripheral lymphocytes and buccal cells of patients and healthy subjects with family history of cancer. The meta-analysis on MN applied in buccal cells of HNC patients was performed on two subgroups of studies. A significant increase of MN frequency in patients compared to healthy controls was observed for the subgroup on oral cancer (243 cases/370 controls, meta-MR = 4.71 95 %CI:2.75-8.06) and HNC (204 patients/163 controls metaMR=2.28 95 %CI:2.02-2.58). A metaMR = 3.27 (95 %CI:1.41-7.59) was obtained for MN applied in peripheral lymphocytes on HNC (160 cases/160 controls). For BC, the analysis of MN in peripheral lymphocytes showed significantly higher values in patients (n = 761) than in controls (n = 788) (meta-MR1.90 95 % CI:1.44-2.49). No statistically significant increase of baseline MN was detected in studies on groups of healthy subjects with BC family history (n = 224) or with BRCA1/2 mutations (n = 101) with respect to the controls. After ex-vivo challenge with ionizing radiation, the meta-analysis revealed a slightly statistically significant increase in MN only in BC patients (n = 614) compared to controls (n = 622)(meta-MR = 1.11 95 %CI:1.02-1.21); no increase was observed in healthy subjects with BC family history carrying or not BRCA1/2 mutations. Significant difference between BC patients (n = 183) and controls (n = 165) was observed by the meta-analysis of data on MN in buccal cells (MR = 3.89 95 %CI:1.54-9.78). The MN assay in buccal cells has some perspective of clinical application in HNC.
对 19 项头颈部癌症 (HNC) 和 21 项乳腺癌 (BC) 的研究进行了系统评价和荟萃分析，以评估微核 (MN) 测定作为癌症风险的预测和预后试验的应用。在这些研究中，MN 试验应用于有癌症家族史的患者和健康受试者的外周血淋巴细胞和口腔颊细胞。对头颈部癌症患者口腔颊细胞 MN 试验的荟萃分析分为两个亚组进行。与健康对照组相比，口腔癌 (243 例/370 例，Meta-MR = 4.71 95%CI:2.75-8.06) 和 HNC (204 例/163 例，Meta-MR=2.28 95%CI:2.02-2.58) 患者的 MN 频率显著增加。在 HNC 中，外周血淋巴细胞中的 MN 应用获得了 MetaMR = 3.27(95%CI:1.41-7.59)(160 例/160 例对照)。对于 BC，外周血淋巴细胞中 MN 的分析显示，患者 (n = 761) 的值明显高于对照组 (n = 788)(Meta-MR1.90 95%CI:1.44-2.49)。在有 BC 家族史的健康受试者 (n = 224) 或有 BRCA1/2 突变的健康受试者 (n = 101) 组中，未检测到基线 MN 显著升高。在体外接受电离辐射后，荟萃分析仅显示 BC 患者 (n = 614) 与对照组 (n = 622) 相比，MN 略有统计学意义的增加 (Meta-MR = 1.11 95%CI:1.02-1.21)；在有或没有 BRCA1/2 突变的有 BC 家族史的健康受试者中，未观察到 MN 增加。在口腔颊细胞 MN 分析中，BC 患者 (n = 183) 与对照组 (n = 165) 的荟萃分析观察到显著差异 (MR = 3.89 95%CI:1.54-9.78)。MN 试验在口腔颊细胞中对头颈部癌症具有一定的临床应用前景。
